Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul;96(7):e29801.
doi: 10.1002/jmv.29801.

Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection

David N Springer  1 , Jeremy V Camp  1 , Stephan W Aberle  1 , Josef Deutsch  2 , Oliver Lammel  3 , Lukas Weseslindtner  1 , Karin Stiasny  1 , Judith H Aberle  1
Affiliations

Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection

David N Springer et al. J Med Virol. 2024 Jul.

Abstract

SARS-CoV-2 Omicron lineages continue to emerge and evolve into new sublineages, causing infection waves throughout 2022 and 2023, which has been attributed to immune escape. We examined neutralizing antibody responses to the recently emerged SARS-CoV-2 JN.1 variant in comparison to ancestral D614G and Omicron BA.1, BA.2, BA.5, and XBB.1.5 variants. We tested 79 human sera from cohorts with different combinations of vaccinations and infections, including 23 individuals who had been repeatedly exposed to Omicron. Individuals with a monovalent XBB.1.5 vaccine booster or XBB.1.5 breakthrough infection had robust antibody levels against all variants tested; however, JN.1 evaded antibodies in individuals after single Omicron BA.1, BA.2 or BA.5 breakthrough infections. Moreover, in the non-vaccinated cohort, serum antibodies demonstrated almost no cross-neutralization activities against D614G, XBB.1.5 and JN.1. after infections with earlier Omicron variants. These findings show that SARS-CoV-2-immunity is heterogeneous, depending on different combinations of vaccinations and infections, and emphasize the importance of considering different immune-backgrounds when evaluating novel variants.

Keywords: JN.1; Omicron 2.86; Omicron breakthrough infection; XBB; neutralizing antibodies.

PubMed Disclaimer

References

REFERENCES

    1. Wang Q, Iketani S, Li Z, et al. Alarming antibody evasion properties of rising SARS‐CoV‐2 BQ and XBB subvariants. Cell. 2023;186(2):279‐286 e278.
    1. Miller J, Hachmann NP, Collier AY, et al. Substantial neutralization escape by SARS‐CoV‐2 Omicron variants BQ.1.1 and XBB.1. N Engl J Med. 2023;388(7):662‐664.
    1. Kaku Y, Okumura K, Padilla‐Blanco M, et al. Virological characteristics of the SARS‐CoV‐2 JN.1 variant. Lancet Infect Dis. 2024;24(2):e82.
    1. Moustsen‐Helms IR, Bager P, Larsen TG, et al. Relative vaccine protection, disease severity, and symptoms associated with the SARS‐CoV‐2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study. Lancet Infect Dis. 2024. doi:10.1016/S1473-3099(24)00220-2
    1. Wannigama DL, Amarasiri M, Phattharapornjaroen P, et al. Increased faecal shedding in SARS‐CoV‐2 variants BA.2.86 and JN.1. Lancet Infect Dis. 2024;24(6):e348‐e350.

Supplementary concepts

LinkOut - more resources